CAS 86347-14-0
:Médétomidine
- ( -)-4-(alpha,2,3-Trimethylbenzyl)imidazole
- (RS)-4-(alpha,2,3-Trimethylbenzyl)imidazol
- 1H-Imidazole, 4-(1-(2,3-dimethylphenyl)ethyl)-
- 1H-Imidazole, 5-[1-(2,3-dimethylphenyl)ethyl]-
- 5-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
- Medetomidina
- Medetomidina [Spanish]
- Medetomidinum
- Medetomidinum [Latin]
- Selektope
- Slectope
- Unii-Mr15E85Mqm
- dl-Medetomidine
- Voir plus de synonymes
Medetomidine
CAS :Formule :C13H16N2Degré de pureté :95%Couleur et forme :SolidMasse moléculaire :200.2795Medetomidine-d5 (d5-Major)
CAS :Produit contrôléApplications Medetomidine-d5 (d5-Major) is an intermediate in the synthesis of Dexmedetomidine-d4 L-Tartrate (d4-Major) (D299006). Dexmedetomidine-d4 L-Tartrate is the labeled salt analogue of Dexmedetomidine (D299000), an α2-Adrenergic agonist; (+)-isomer of Medetomidine; sedative; analgesic.
References Rajala, R., et al.: Eur. J. Pharm. Sci., 1, 219 (1994); Jalonen, J., et al.: Anesthesiology, 86, 331 (1997); Talke, P., et al.: Anesth. Analg., 85, 1136 (1997); Bhana, N., et al.: Drugs, 59, 263 (2000)Formule :C13D5H11N2Couleur et forme :NeatMasse moléculaire :205.31Medetomidine
CAS :Medetomidine (MPV785 free base) is a selective α2-adrenoceptor agonist, with sedative and analgesic and vasoconstrictive hypoxic , in small animal anesthesia.Formule :C13H16N2Degré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :200.28Ref: TM-T21492
2mg38,00€5mg57,00€10mg77,00€25mg128,00€50mg193,00€100mg290,00€200mg447,00€1mL*10mM (DMSO)62,00€Medetomidine-d4
CAS :Produit contrôléFormule :C13D4H12N2Couleur et forme :NeatMasse moléculaire :204.304Medetomidine
CAS :Produit contrôléMedetomidine is an experimental drug that belongs to the group of solubility data. It is a highly selective α-2 adrenergic agonist that has been used in experimental studies to study the central and peripheral effects of the drug. Medetomidine has been shown to induce natriuretic peptide levels and intracellular calcium levels in anesthetized animals. This drug also affects locomotor activity and enzyme activities, which may be due to its ability to increase corticosterone levels. The dexmedetomidine-medetomidine combination was found to produce sedation with minimal cardiovascular effects. The model system used for this study consisted of sedated rats receiving a single intravenous injection of medetomidine or dexmedetomidine alone or in combination with medetomidine. Medetomidine is soluble in water and methanol, but insoluble in ethanol and ether.
Formule :C13H16N2Degré de pureté :Min. 95%Masse moléculaire :200.28 g/mol





